5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Clinical O
Worsening/Suicide O
Risk O
: O
Monitor O
for O
clinical O
worsening O
and O
suicide O
risk O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Risk O
increases O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
. O

Discontinue O
Effexor O
XR O
and O
initiate O
supportive O
treatment O
if O
serotonin O
syndrome O
occurs O
( O
4.2 O
, O
5.2 O
, O
7.3 O
) O
. O

* O
Elevations O
in O
Blood O
Pressure O
: O
Control O
hypertension O
before O
initiating O
treatment O
. O

Monitor O
blood O
pressure O
regularly O
during O
treatment O
( O
5.3 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Effexor O
XR O
may O
increase O
risk O
of O
bleeding O
events O
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding O
associated O
with O
the O
concomitant O
use O
of O
Effexor O
XR O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.4 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Angle O
closure O
glaucoma O
has O
occurred O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
treated O
with O
antidepressants O
. O

( O
5.5 O
) O
. O

* O
Activation O
of O
Mania/Hypomania O
: O
Use O
cautiously O
in O
patients O
with O
bipolar O
disorder O
. O

Caution O
patients O
about O
the O
risk O
of O
activation O
of O
mania/hypomania O
( O
5.6 O
) O
. O

5.1 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Children O
, O
Adolescents O
, O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
studies O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
MDD B-Not_AE_Candidate
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
studies O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
Obsessive B-Not_AE_Candidate
Compulsive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
studies O
of O
9 O
antidepressant O
drugs O
in O
over O
4,400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
studies O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
studies O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
versus O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1,000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
: O
Difference O
in O
the O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1,000 O
Patients O
Treated O
versus O
Placebo O
Age O
Range O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
= O
65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
studies O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
studies O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer O
term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
studies O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
MDD B-Not_AE_Candidate
, O
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening O
of O
depression B-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation B-NonOSE_AE
can I-NonOSE_AE
be I-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
certain I-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
and O
Dosage O
and O
Administration O
( O
2.8 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
MDD B-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
Effexor O
XR O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
capsules O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
studies O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
Effexor O
XR O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Effexor O
XR O
alone O
, O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
others O
, O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
coma B-NonOSE_AE
) O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
; O
seizures B-NonOSE_AE
and O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Effexor O
XR O
with O
MAOIs O
( O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
) O
is O
contraindicated O
. O

Effexor O
XR O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
a O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Effexor O
XR O
. O

Effexor O
XR O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
and O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

If O
concomitant O
use O
of O
Effexor O
XR O
with O
other O
serotonergic O
drugs O
( O
e.g. O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
mirtazapine O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
amphetamines O
, O
tryptophan O
, O
or O
St O
. O
John O
's O
wort O
) O
is O
clinically O
warranted O
, O
careful O
observation O
of O
the O
patient O
is O
advised O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

Patients O
should O
be O
made O
aware O
of O
the O
potential O
risk O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Treatment O
with O
Effexor O
XR O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
, O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Elevations O
in O
Blood O
Pressure O
In O
controlled O
trials O
, O
there O
were O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic O
and O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
as O
well O
as O
cases O
of O
sustained O
hypertension B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Monitor O
blood O
pressure O
before O
initiating O
treatment O
with O
Effexor O
XR O
and O
regularly O
during O
treatment O
. O

Control O
pre-existing O
hypertension B-Not_AE_Candidate
before O
initiating O
treatment O
with O
Effexor O
XR O
. O

Use O
caution O
in O
treating O
patients O
with O
pre-existing O
hypertension B-Not_AE_Candidate
or O
cardiovascular B-Not_AE_Candidate
or O
cerebrovascular O
conditions I-Not_AE_Candidate
that O
might O
be O
compromised O
by O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Sustained O
blood B-NonOSE_AE
pressure I-NonOSE_AE
elevation I-NonOSE_AE
can O
lead O
to O
adverse O
outcomes O
. O

Cases O
of O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
requiring O
immediate O
treatment O
have O
been O
reported O
with O
Effexor O
XR O
. O

Consider O
dose O
reduction O
or O
discontinuation O
of O
treatment O
for O
patients O
who O
experience O
a O
sustained O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Across O
all O
clinical O
studies O
with O
Effexor O
, O
1.4 O
% O
of O
patients O
in O
the O
Effexor O
XR O
treated O
groups O
experienced O
a O
> O
=15 O
mm O
Hg O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
SDBP O
) O
> O
= O
105 O
mm O
Hg O
, O
compared O
to O
0.9 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Similarly O
, O
1 O
% O
of O
patients O
in O
the O
Effexor O
XR O
treated O
groups O
experienced O
a O
> O
= O
20 O
mm O
Hg O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
SSBP O
) O
with O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
, O
compared O
to O
0.3 O
% O
of O
patients O
in O
the O
placebo O
groups O
[ O
see O
Table O
10 O
in O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Effexor O
XR O
treatment O
was O
associated O
with O
sustained B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( O
defined O
as O
treatment-emergent O
SDBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mm I-NonOSE_AE
Hg I-NonOSE_AE
and O
> O
= O
10 O
mm O
Hg O
above O
baseline O
for O
three O
consecutive O
on-therapy O
visits O
[ O
see O
Table O
11 O
in O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

An O
insufficient O
number O
of O
patients O
received O
mean O
doses O
of O
Effexor O
XR O
over O
300 O
mg O
per O
day O
in O
clinical O
studies O
to O
fully O
evaluate O
the O
incidence O
of O
sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
at O
these O
higher O
doses O
. O

5.4 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Effexor O
XR O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
, O
ranging O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
petechiae B-OSE_Labeled_AE
, O
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
to O
life-threatening O
hemorrhage B-OSE_Labeled_AE
. O

Concomitant O
use O
of O
aspirin O
, O
Nonsteroidal O
Anti-Inflammatory O
Drugs O
( O
NSAIDs O
) O
, O
warfarin O
, O
and O
other O
anti-coagulants O
or O
other O
drugs O
known O
to O
affect O
platelet O
function O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Effexor O
XR O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.5 O
Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Effexor O
XR O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

5.6 O
Activation O
of O
Mania/Hypomania O
Mania B-OSE_Labeled_AE
or O
hypomania B-OSE_Labeled_AE
was O
reported O
in O
Effexor O
XR O
treated O
patients O
in O
the O
premarketing O
studies O
in O
MDD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
, O
and O
PD B-Not_AE_Candidate
( O
see O
Table O
2 O
) O
. O

Mania B-NonOSE_AE
/ O
hypomania B-NonOSE_AE
has O
also O
been O
reported O
in O
a O
small O
proportion O
of O
patients O
with O
mood B-Not_AE_Candidate
disorders I-Not_AE_Candidate
who O
were O
treated O
with O
other O
marketed O
drugs O
to O
treat O
MDD B-Not_AE_Candidate
. O

Effexor O
XR O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
or O
hypomania B-Not_AE_Candidate
. O

Table O
2 O
: O
Incidence O
( O
% O
) O
of O
Mania B-OSE_Labeled_AE
or O
Hypomania B-OSE_Labeled_AE
Reported O
in O
Effexor O
XR O
Treated O
Patients O
in O
the O
Premarketing O
Studies O
Indication O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
0.3 O
0.0 O
GAD B-Not_AE_Candidate
0.0 O
0.2 O
SAD B-Not_AE_Candidate
0.2 O
0.0 O
PD B-Not_AE_Candidate
0.1 O
0.0 O
5.7 O
Discontinuation O
Syndrome O
Discontinuation B-NonOSE_AE
symptoms I-NonOSE_AE
have O
been O
systematically O
evaluated O
in O
patients O
taking O
venlafaxine O
, O
including O
prospective O
analyses O
of O
clinical O
studies O
in O
GAD B-Not_AE_Candidate
and O
retrospective O
surveys O
of O
studies O
in O
MDD B-Not_AE_Candidate
and O
SAD B-Not_AE_Candidate
. O

Abrupt O
discontinuation B-OSE_Labeled_AE
or I-OSE_Labeled_AE
dose I-OSE_Labeled_AE
reduction I-OSE_Labeled_AE
of I-OSE_Labeled_AE
venlafaxine I-OSE_Labeled_AE
at I-OSE_Labeled_AE
various I-OSE_Labeled_AE
doses I-OSE_Labeled_AE
has I-OSE_Labeled_AE
been I-OSE_Labeled_AE
found I-OSE_Labeled_AE
to I-OSE_Labeled_AE
be I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
appearance I-OSE_Labeled_AE
of I-OSE_Labeled_AE
new I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
the O
frequency O
of O
which O
increased O
with O
increased O
dose O
level O
and O
with O
longer O
duration O
of O
treatment O
. O

Reported O
symptoms O
include O
agitation B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
impaired B-NonOSE_AE
coordination O
and O
balance I-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
dry B-NonOSE_AE
mouth I-NonOSE_AE
, O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
fasciculation B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
flu B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
symptoms I-NonOSE_AE
, O
headaches B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
nightmares B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
including O
shock B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
electrical I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
somnolence B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
vertigo B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
. O

During O
marketing O
of O
Effexor O
XR O
, O
other O
SNRIs O
, O
and O
SSRIs O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurring I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
these O
drugs O
, O
particularly O
when O
abrupt O
, O
including O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesia B-NonOSE_AE
, O
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

While O
these O
events O
are O
generally O
self-limiting O
, O
there O
have O
been O
reports O
of O
serious O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms O
when O
discontinuing O
treatment O
with O
Effexor O
XR O
. O

A O
gradual O
reduction O
in O
the O
dose O
, O
rather O
than O
abrupt O
cessation O
, O
is O
recommended O
whenever O
possible O
. O

If O
intolerable O
symptoms B-NonOSE_AE
occur I-NonOSE_AE
following I-NonOSE_AE
a I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dose I-NonOSE_AE
or I-NonOSE_AE
upon I-NonOSE_AE
discontinuation I-NonOSE_AE
of I-NonOSE_AE
treatment I-NonOSE_AE
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
, O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.8 O
) O
] O
. O

5.8 O
Seizures O
Seizures B-OSE_Labeled_AE
have O
occurred O
with O
venlafaxine O
therapy O
. O

Effexor O
XR O
, O
like O
many O
antidepressants O
, O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
and O
should O
be O
discontinued O
in O
any O
patient O
who O
develops O
seizures B-NonOSE_AE
. O

[ O
Must O
mitigate O
the O
risk O
: O
Risk O
factors O
, O
concomitant O
meds O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
. O
] O

5.9 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
can O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Effexor O
XR O
. O

In O
many O
cases O
, O
the O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
Syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Inappropriate I-OSE_Labeled_AE
Antidiuretic I-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
secretion O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SSRIs O
and O
SNRIs O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Also O
, O
patients O
taking O
diuretics O
, O
or O
those O
who O
are O
otherwise O
volume-depleted O
, O
may O
be O
at O
greater O
risk O
. O

Consider O
discontinuation O
of O
Effexor O
XR O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
, O
and O
institute O
appropriate O
medical O
intervention O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.10 O
Weight O
and O
Height B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
Weight O
Changes O
The O
average O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
and O
incidence O
of O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
percentage O
of O
patients O
who O
lost O
3.5 O
% O
or O
more O
) O
in O
the O
placebo-controlled O
pediatric O
studies O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
are O
shown O
in O
Tables O
3 O
and O
4 O
. O

Table O
3 O
: O
Average O
Change O
in O
Body O
Weight O
( O
kg O
) O
From O
Beginning O
of O
Treatment O
in O
Pediatric O
Patients O
in O
Double-blind O
, O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
4 O
pooled O
studies O
, O
8 O
weeks O
) O
-0.45 O
( O
n O
= O
333 O
) O
+0.77 O
( O
n O
= O
333 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
-0.75 O
( O
n O
= O
137 O
) O
+0.76 O
( O
n O
= O
148 O
) O
Table O
4 O
: O
Incidence O
( O
% O
) O
of O
Pediatric O
Patients O
Experiencing O
Weight O
Loss O
( O
3.5 O
% O
or O
more O
) O
in O
Double-blind O
, O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
4 O
pooled O
studies O
, O
8 O
weeks O
) O
18 O
[ O
note O
: O
p O
< O
0.001 O
versus O
placebo O
] O
( O
n O
= O
333 O
) O
3.6 O
( O
n O
= O
333 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
47 O
( O
n O
= O
137 O
) O
14 O
( O
n O
= O
148 O
) O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
was O
not O
limited O
to O
patients O
with O
treatment-emergent O
anorexia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

The O
risks O
associated O
with O
longer O
term O
Effexor O
XR O
use O
were O
assessed O
in O
an O
open-label O
MDD B-Not_AE_Candidate
study O
of O
children O
and O
adolescents O
who O
received O
Effexor O
XR O
for O
up O
to O
six O
months O
. O

The O
children O
and O
adolescents O
in O
the O
study O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
that I-OSE_Labeled_AE
were I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
, O
based O
on O
data O
from O
age- O
and O
sex-matched O
peers O
. O

The O
difference B-OSE_Labeled_AE
between I-OSE_Labeled_AE
observed I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
and I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
larger O
for O
children O
( O
< O
12 O
years O
old O
) O
than O
for O
adolescents O
( O
> O
= O
12 O
years O
old O
) O
. O

Height O
Changes O
Table O
5 O
shows O
the O
average O
height B-NonOSE_AE
increase I-NonOSE_AE
in O
pediatric O
patients O
in O
the O
short-term O
, O
placebo-controlled O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
studies O
. O

The O
differences O
in O
height O
increases O
in O
GAD B-Not_AE_Candidate
and O
MDD B-Not_AE_Candidate
studies O
were O
most O
notable O
in O
patients O
younger O
than O
twelve O
. O

Table O
5 O
: O
Average O
Height O
Increases O
( O
cm O
) O
in O
Pediatric O
Patients O
in O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
8 O
weeks O
) O
0.8 O
( O
n O
= O
146 O
) O
0.7 O
( O
n O
= O
147 O
) O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
0.3 O
[ O
note O
: O
p O
= O
0.041 O
] O
( O
n O
= O
122 O
) O
1.0 O
( O
n O
= O
132 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
1.0 O
( O
n O
= O
109 O
) O
1.0 O
( O
n O
= O
112 O
) O
In O
the O
six-month O
, O
open-label O
MDD B-Not_AE_Candidate
study O
, O
children O
and O
adolescents O
had O
height B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
that O
were O
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
, O
based O
on O
data O
from O
age- O
and O
sex-matched O
peers O
. O

The O
difference O
between O
observed O
and O
expected O
growth O
rates O
was O
larger O
for O
children O
( O
< O
12 O
years O
old O
) O
than O
for O
adolescents O
( O
> O
= O
12 O
years O
old O
) O
. O

5.11 O
Appetite B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
reported O
as O
treatment B-OSE_Labeled_AE
- I-OSE_Labeled_AE
emergent I-OSE_Labeled_AE
anorexia I-OSE_Labeled_AE
) O
was O
more O
commonly O
observed O
in O
Effexor O
XR O
treated O
patients O
versus O
placebo-treated O
patients O
in O
the O
premarketing O
evaluation O
of O
Effexor O
XR O
for O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
( O
see O
Table O
6 O
) O
. O

Table O
6 O
: O
Incidence O
( O
% O
) O
of O
Decreased O
Appetite O
and O
Associated O
Discontinuation O
RatesThe O
discontinuation O
rates O
for O
weight O
loss O
were O
0.7 O
% O
for O
patients O
receiving O
either O
Effexor O
XR O
or O
placebo O
. O

( O
% O
) O
in O
Pediatric O
Patients O
in O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Incidence O
Discontinuation O
Placebo O
Incidence O
Discontinuation O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
pooled O
, O
8 O
weeks O
) O
10 O
0.0 O
3 O
- O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
22 O
0.7 O
3 O
0.0 O
5.12 O
Interstitial O
Lung O
Disease O
and O
Eosinophilic O
Pneumonia O
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
eosinophilic B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
associated O
with O
venlafaxine O
therapy O
have O
been O
rarely O
reported O
. O

The O
possibility O
of O
these O
adverse O
events O
should O
be O
considered O
in O
venlafaxine-treated O
patients O
who O
present O
with O
progressive O
dyspnea B-NonOSE_AE
, O
cough B-NonOSE_AE
or O
chest B-NonOSE_AE
discomfort I-NonOSE_AE
. O

Such O
patients O
should O
undergo O
a O
prompt O
medical O
evaluation O
, O
and O
discontinuation O
of O
venlafaxine O
therapy O
should O
be O
considered O
. O

